GIOTRIF® :
The 1^st choice in 1^st-line

Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1^st-line EGFR M+ NSCLC^1-4*

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study

Document ID: RD-123384

08/09/2020

Author: Boehringer Ingelheim

123,000
Views

100k 340